Skip Navigation

JNCI Journal of the National Cancer Institute 2008 100(20):1417; doi:10.1093/jnci/djn372
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

In This Issue

The first 10% of the full text of this article appears below.

Accuracy of a Biomarker Used for Classification or Prediction

Research methods for biomarker evaluation have lagged behind those for evaluating therapeutic treatments. Although a phased approach to the development of biomarkers and reporting guidelines is available, a comprehensive set of guidelines for study design has not been presented. Pepe et al. (p. 1432) describe a nested case–control study design, called the prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design. This study design involves prospective collection of specimens from a study cohort, random selection of specimens from case patients and control subjects in the cohort, and the blinded assay of specimens. Details of the study design are described in relation . . . [Full Text of this Article]

Association of NSAID Use and Reduced Breast Cancer Risk

Tamoxifen and Time to Diagnosis of ER-Negative Breast Cancer

Sorafenib for Older Patients with Renal Cell Carcinoma

A Mediator of Malignant Pleural Effusion in Mice

Male Breast Cancer Risk Factors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial
Tim Eisen, Stéphane Oudard, Cezary Szczylik, Gwenaelle Gravis, Hans Heinzer, Richard Middleton, Frank Cihon, Sibyl Anderson, Sonalee Shah, Ronald Bukowski, Bernard Escudier, and for the TARGET Study Group
J Natl Cancer Inst 2008 100: 1454-1463. [Abstract] [Full Text] [PDF]

Tamoxifen Chemoprevention Treatment and Time to First Diagnosis of Estrogen Receptor–Negative Breast Cancer
Yu Shen, Joseph P. Costantino, and Jing Qin
J Natl Cancer Inst 2008 100: 1448-1453. [Abstract] [Full Text] [PDF]

Breast Cancer and Use of Nonsteroidal Anti-inflammatory Drugs: A Meta-analysis
Bahi Takkouche, Carlos Regueira-Méndez, and Mahyar Etminan
J Natl Cancer Inst 2008 100: 1439-1447. [Abstract] [Full Text] [PDF]

A Central Role for Tumor-derived Monocyte Chemoattractant Protein-1 in Malignant Pleural Effusion
Georgios T. Stathopoulos, Ioannis Psallidas, Ardiana Moustaki, Charalampos Moschos, Androniki Kollintza, Sophia Karabela, Ilias Porfyridis, Spyridoula Vassiliou, Marilena Karatza, Zongmin Zhou, Myungsoo Joo, Timothy S. Blackwell, Charis Roussos, Daniel Graf, and Ioannis Kalomenidis
J Natl Cancer Inst 2008 100: 1464-1476. [Abstract] [Full Text] [PDF]

Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design
Margaret S. Pepe, Ziding Feng, Holly Janes, Patrick M. Bossuyt, and John D. Potter
J Natl Cancer Inst 2008 100: 1432-1438. [Abstract] [Full Text] [PDF]

Prospective Evaluation of Risk Factors for Male Breast Cancer
Louise A. Brinton, Douglas A. Richesson, Gretchen L. Gierach, James V. Lacey, Jr, Yikyung Park, Albert R. Hollenbeck, and Arthur Schatzkin
J Natl Cancer Inst 2008 100: 1477-1481. [Abstract] [Full Text] [PDF]

The Process to Discover and Develop Biomarkers for Cancer: A Work in Progress
David F. Ransohoff
J Natl Cancer Inst 2008 100: 1419-1420. [Extract] [Full Text] [PDF]

Modulation of Breast Cancer Risk by Nonsteroidal Anti-inflammatory Drugs
Louise R. Howe and Scott M. Lippman
J Natl Cancer Inst 2008 100: 1420-1423. [Extract] [Full Text] [PDF]